Search

Your search keyword '"Leone, Aldo"' showing total 19 results
Start Over Author "Leone, Aldo"
19 results on '"Leone, Aldo"'

1. Safety of Subcutaneous Daratumumab in Anti-CD38 Monoclonal Antibody-Naïve Patients with Plasma Cell Disorders: A Multicenter Real-Life Experience

Author

De Novellis, Danilo, Fontana, Raffaele, Palmieri, Salvatore, Della Pepa, Roberta, Di Perna, Maria, Cetani, Giusy, Esposito, Daniela, Amendola, Angela, Delle Cave, Giuseppe, Serio, Bianca, Morini, Denise, Rizzo, Michela, Mettivier, Laura, Trastulli, Fabio, Rocco, Stefano, Pagano, Anastasia, Barbato, Serafina, Leone, Aldo, La Magna, Martina, Bianco, Rosario, Rascato, Gabriella, Carobene, Angela, Cuffa, Bianca, Iannalfo, Marialuigia, Giudice, Valentina, Svanera, Gino, Annunziata, Mario, Pizzuti, Michele, Frigeri, Ferdinando, Califano, Catello, Ferrara, Felicetto, Pane, Fabrizio, and Selleri, Carmine

Published
2023
Full Text
View/download PDF

2. Mitochondrial sAC-cAMP-PKA Axis Modulates the ΔΨm-Dependent Control Coefficients of the Respiratory Chain Complexes: Evidence of Respirasome Plasticity

Author

Scrima, Rosella, primary, Cela, Olga, additional, Rosiello, Michela, additional, Nabi, Ari Qadir, additional, Piccoli, Claudia, additional, Capitanio, Giuseppe, additional, Tucci, Francesco Antonio, additional, Leone, Aldo, additional, Quarato, Giovanni, additional, and Capitanio, Nazzareno, additional

Published
2023
Full Text
View/download PDF

4. P1050: NEXT GENERATION SEQUECING CONTRIBUTES TO DEFINE PH-NEGATIVE MYELOPROLIFERATIVE NEOPLASM CLINICAL PHENOTYPE

Author

Leone, Aldo, primary, Conversano, Italia, additional, Barbato, Serafina, additional, Donnarumma, Giuseppina, additional, Gaeta, Giuseppe, additional, Iannotta, Raffaella, additional, Muriano, Francesco, additional, Reina, Raffaella, additional, Romano, Martina, additional, Iula, Rossella, additional, Scarpa, Alessia, additional, Martinelli, Vincenzo, additional, Pane, Fabrizio, additional, and Pugliese, Novella, additional

Published
2023
Full Text
View/download PDF

5. PB2204: HIGH SERUM FERRITIN AT INITIAL DIAGNOSIS IS A PREDICTOR OF BONE MARROW FIBROSIS IN PH NEGATIVE CHRONIC MYELOPROLIFERATIVE NEOPLASMS

Author

Leone, Aldo, primary, Reina, Raffaella, additional, Romano, Martina, additional, Muriano, Francesco, additional, Gaeta, Giuseppe, additional, Iannotta, Raffaella, additional, Donnarumma, Giuseppina, additional, Conversano, Italia, additional, Barbato, Serafina, additional, Iula, Rossella, additional, Cacace, Andrea, additional, Martinelli, Vincenzo, additional, Pane, Fabrizio, additional, and Pugliese, Novella, additional

Published
2023
Full Text
View/download PDF

6. Mitochondrial sAC-cAMP-PKA Axis Modulates the ΔΨ m -Dependent Control Coefficients of the Respiratory Chain Complexes: Evidence of Respirasome Plasticity.

Author

Scrima, Rosella, Cela, Olga, Rosiello, Michela, Nabi, Ari Qadir, Piccoli, Claudia, Capitanio, Giuseppe, Tucci, Francesco Antonio, Leone, Aldo, Quarato, Giovanni, and Capitanio, Nazzareno

Subjects
MEMBRANE potential, MITOCHONDRIA, MITOCHONDRIAL membranes, DYNAMIC balance (Mechanics), OXYGEN consumption
Abstract

The current view of the mitochondrial respiratory chain complexes I, III and IV foresees the occurrence of their assembly in supercomplexes, providing additional functional properties when compared with randomly colliding isolated complexes. According to the plasticity model, the two structural states of the respiratory chain may interconvert, influenced by the intracellular prevailing conditions. In previous studies, we suggested the mitochondrial membrane potential as a factor for controlling their dynamic balance. Here, we investigated if and how the cAMP/PKA-mediated signalling influences the aggregation state of the respiratory complexes. An analysis of the inhibitory titration profiles of the endogenous oxygen consumption rates in intact HepG2 cells with specific inhibitors of the respiratory complexes was performed to quantify, in the framework of the metabolic flux theory, the corresponding control coefficients. The attained results, pharmacologically inhibiting either PKA or sAC, indicated that the reversible phosphorylation of the respiratory chain complexes/supercomplexes influenced their assembly state in response to the membrane potential. This conclusion was supported by the scrutiny of the available structure of the CI/CIII2/CIV respirasome, enabling us to map several PKA-targeted serine residues exposed to the matrix side of the complexes I, III and IV at the contact interfaces of the three complexes. [ABSTRACT FROM AUTHOR]

Published
2023
Full Text
View/download PDF

7. Efficacy and safety of belantamab-mafodotin in triple-refractory multiple myeloma patients: A multicentric real-life experience

Author

Iula, Rossella, primary, De Novellis, Danilo, additional, Trastulli, Fabio, additional, Della Pepa, Roberta, additional, Fontana, Raffaele, additional, Carobene, Angela, additional, Di Perna, Maria, additional, D’Ambrosio, Alessandro, additional, Romano, Martina, additional, Leone, Aldo, additional, De Fazio, Laura, additional, Fiumarella, Alfonso, additional, Gaeta, Giuseppe, additional, Marafioti, Violetta, additional, Barbato, Serafina, additional, Palmieri, Salvatore, additional, Rocco, Stefano, additional, Serio, Bianca, additional, Califano, Catello, additional, Pane, Fabrizio, additional, Ferrara, Felicetto, additional, Giudice, Valentina, additional, Selleri, Carmine, additional, and Catalano, Lucio, additional

Published
2022
Full Text
View/download PDF

8. Sulfur Exafluoride Contrast-Enhanced Ultrasound Showing Early Wash-Out of Marked Degree Identifies Lymphoma Invasion of Spleen with Excellent Diagnostic Accuracy: A Monocentric Study of 260 Splenic Nodules

Author

Picardi, Marco, primary, Giordano, Claudia, additional, Trastulli, Fabio, additional, Leone, Aldo, additional, Della Pepa, Roberta, additional, Pugliese, Novella, additional, Iula, Rossella, additional, Delle Cave, Giuseppe, additional, Rascato, Maria Gabriella, additional, Esposito, Maria, additional, Vigliar, Elena, additional, Troncone, Giancarlo, additional, Mascolo, Massimo, additional, Russo, Daniela, additional, Persico, Marcello, additional, and Pane, Fabrizio, additional

Published
2022
Full Text
View/download PDF

9. Rituximab-Containing Risk-Adapted Treatment Strategy in Nodular Lymphocyte Predominant Hodgkin Lymphoma: 7-Years Follow-Up

Author

Pugliese, Novella, primary, Picardi, Marco, additional, Della Pepa, Roberta, additional, Giordano, Claudia, additional, Muriano, Francesco, additional, Leone, Aldo, additional, Delle Cave, Giuseppe, additional, D’Ambrosio, Alessandro, additional, Marafioti, Violetta, additional, Rascato, Maria Gabriella, additional, Russo, Daniela, additional, Mascolo, Massimo, additional, and Pane, Fabrizio, additional

Published
2021
Full Text
View/download PDF

10. Correspondence in reference to the previously published Epub manuscript by Peter Hokland et al . ‘How I treat advanced Hodgkin lymphoma – a global view’. Br J Haematol . 2020;190:837–50

Author

Picardi, Marco, primary, Giordano, Claudia, additional, Della Pepa, Roberta, additional, Pugliese, Novella, additional, Leone, Aldo, additional, Mascolo, Massimo, additional, Daniela, Russo, additional, Vigliar, Elena, additional, Troncone, Giancarlo, additional, Salvatore, Claudia, additional, and Pane, Fabrizio, additional

Published
2021
Full Text
View/download PDF

11. Correspondence in reference to previously published manuscript: “Faouzi Djebbari et al. Efficacy and infection morbidity of front‐line immuno‐chemotherapy in follicular lymphoma. Eur J Haematol. 2020; 105: 667‐671”

Author

Picardi, Marco, primary, Giordano, Claudia, additional, Della Pepa, Roberta, additional, Cerchione, Claudio, additional, Pugliese, Novella, additional, Leone, Aldo, additional, Vitiello, Selenia, additional, and Pane, Fabrizio, additional

Published
2021
Full Text
View/download PDF

17. Correspondence in reference to the previously published Epub manuscript by Peter Hokland et al . ‘How I treat advanced Hodgkin lymphoma – a global view’. Br J Haematol . 2020;190:837–50

Author

Giancarlo Troncone, Massimo Mascolo, Russo Daniela, Claudia Salvatore, Aldo Leone, Fabrizio Pane, Marco Picardi, Elena Vigliar, Roberta Della Pepa, Novella Pugliese, Claudia Giordano, Picardi, Marco, Giordano, Claudia, Della Pepa, Roberta, Pugliese, Novella, Leone, Aldo, Mascolo, Massimo, Russo, Daniela, Vigliar, Elena, Troncone, Giancarlo, Salvatore, Claudia, and Pane, Fabrizio

Subjects
medicine.medical_specialty, Lymphoma, business.industry, MEDLINE, medicine, Humans, Hodgkin lymphoma, Hematology, business, Hodgkin Disease, Dermatology
Published
2021

18. Regarding 'Hepatitis B Surface Antigen Positivity Is an Independent Unfavorable Prognostic Factor in Diffuse Large B-Cell Lymphoma in the Rituximab Era'

Author

Giuseppe Delle Cave, Giuseppe Gentile, Aldo Leone, Fabrizio Pane, Marco Picardi, Rossella Iula, Claudia Giordano, Novella Pugliese, Roberta Della Pepa, Picardi, Marco, Giordano, Claudia, Della Pepa, Roberta, Pugliese, Novella, Leone, Aldo, Delle Cave, Giuseppe, Iula, Rossella, Gentile, Giuseppe, and Pane, Fabrizio

Subjects
Cancer Research, medicine.medical_specialty, Prognostic factor, Letter to the editor, hepatitis b virus, Hematologic Malignancies, HBV reactivation, lymphoma, Hepatitis b surface antigen, Gastroenterology, 03 medical and health sciences, 0302 clinical medicine, Internal medicine, hemic and lymphatic diseases, medicine, Humans, Hepatitis B Surface Antigens, business.industry, virus diseases, Retrospective cohort study, Hepatitis B, HBV reactivation, hepatitis b virus, lymphoma, medicine.disease, Prognosis, digestive system diseases, Lymphoma, Oncology, Vincristine, 030220 oncology & carcinogenesis, 030211 gastroenterology & hepatology, Rituximab, Lymphoma, Large B-Cell, Diffuse, business, Diffuse large B-cell lymphoma, medicine.drug
Abstract

BACKGROUND: Patients with diffuse large B‐cell lymphoma (DLBCL) with concurrent hepatitis B surface antigen (HBsAg)‐positive hepatitis B virus (HBV) infection have distinct clinical features. Nevertheless, the prognostic value of HBsAg in DLBCL in the rituximab era remains unclear. MATERIALS AND METHODS: We conducted a retrospective cohort study to investigate the clinical relevance of HBsAg in immunocompetent patients with DLBCL treated with homogeneous rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisone between 2002 and 2016. RESULTS: Among 416 analyzed patients, 98 (23.6%) were HBsAg positive. HBsAg positivity was associated with a younger age and more advanced stage at diagnosis, more frequent hepatic impairment during perichemotherapy, and a trend of higher National Comprehensive Cancer Network‐International Prognostic Index (NCCN‐IPI) score at diagnosis. Compared with the HBsAg‐negative patients, the HBsAg‐positive patients had a lower overall response rate (76.5% vs. 85.5%, p = .043), poorer 5‐year overall survival (OS) rate (57.2% vs. 73.5%, p < .001), and shorter 5‐year progression‐free survival (PFS) rate (47.2% vs. 60.7%, p = .013). Multivariate analyses showed that HBsAg positivity was an independent unfavorable prognostic indicator for OS and PFS. A scoring system incorporating HBsAg positivity, the NCCN‐IPI score, and serum albumin levels proved to be useful for stratifying prognostically relevant subgroups of patients with DLBCL. CONCLUSION: This study demonstrated that HBV infection is uniquely relevant to DLBCL. HBsAg might serve as a novel biomarker to improve clinical risk stratification of patients with DLBCL in areas with high prevalence of HBV infection. Further research investigating the etiopathogenesis of HBV infection in DLBCL is imperative. IMPLICATIONS FOR PRACTICE: A considerable disparity exists regarding the prognostic relevance of hepatitis B surface antigen (HBsAg)‐positive hepatitis B virus (HBV) infection in patients with diffuse large B‐cell lymphoma (DLBCL). In this large, retrospective cohort study from an area with high prevalence of HBV infection, the authors demonstrated that HBsAg was an independent unfavorable factor significantly associated with survival, highlighting its potential as a novel prognostic indicator to improve the risk stratification of patients with DLBCL in the rituximab era.

Published
2020

19. Correspondence in reference to previously published manuscript: 'Faouzi Djebbari et al. Efficacy and infection morbidity of front-line immuno-chemotherapy in follicular lymphoma. Eur J Haematol. 2020; 105: 667-671'

Author

Aldo Leone, Marco Picardi, Claudia Giordano, Selenia Vitiello, Claudio Cerchione, Fabrizio Pane, Novella Pugliese, Roberta Della Pepa, Picardi, Marco, Giordano, Claudia, Della Pepa, Roberta, Cerchione, Claudio, Pugliese, Novella, Leone, Aldo, Vitiello, Selenia, and Pane, Fabrizio

Subjects
Oncology, Bendamustine, medicine.medical_specialty, Vincristine, Cyclophosphamide, Follicular lymphoma, Infections, Letter to the Editors, 03 medical and health sciences, 0302 clinical medicine, rituximab, immune system diseases, Prednisone, hemic and lymphatic diseases, Internal medicine, Antineoplastic Combined Chemotherapy Protocols, Medicine, Bendamustine Hydrochloride, Humans, Doxorubicin, antimicrobial prophylaxis, bendamustine, Letter to the Editor, Lymphoma, Follicular, business.industry, Incidence (epidemiology), Hematology, General Medicine, medicine.disease, Leukemia, Lymphocytic, Chronic, B-Cell, Treatment Outcome, 030220 oncology & carcinogenesis, indolent lymphoma, Rituximab, Morbidity, business, 030215 immunology, medicine.drug
Abstract

Rituximab and cyclophosphamide-containing regimens (cyclophosphamide, vincristine, prednisone with or without doxorubicin) had been predominantly used as standard immunochemotherapy for symptomatic indolent B-cell lymphomas (i-BCLs) until the recent introduction of bendamustine plus rituximab schedule1 . However, the increased incidence of opportunistic infections following bendamustine exposure have raised questions regarding its safety and widespread adoption2 .

Published
2020

Catalog

Books, media, physical & digital resources
See catalog results